Novel CAR constructs are being developed to specifically target EBV-related antigens such as LMP1 and LMP2, which are selectively expressed on the surface of EBV-transformed cells, allowing for more direct and virus-specific tumor killing (62, 63). Here, PDLIM7 is linked to neoplasm.